Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBACCA) nested within a compassionate use program
暂无分享，去创建一个
L. Mineur | A. Kramar | A. Adenis | T. André | D. Tougeron | S. Clisant | J. Phelip | B. Paule | C. de la Fouchardière | P. Burtin | P. Etienne | J. Wallet | L. Dourthe | C. de la Fouchardiére
[1] D. Sargent,et al. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial. , 2015, The Lancet. Oncology.
[2] Ying Cheng,et al. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial. , 2015, The Lancet. Oncology.
[3] A. Grothey,et al. LBA-05Results from the large, open-label phase 3b CONSIGN study of regorafenib in patients with previously treated metastatic colorectal cancer , 2015 .
[4] H. Lenz,et al. Efficacy of chemotherapy after treatment with regorafenib in metastatic colorectal cancer (mCRC). , 2015 .
[5] D. Sargent,et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial , 2013, The Lancet.
[6] Martin Büchert,et al. A Phase I Dose–Escalation Study of Regorafenib (BAY 73–4506), an Inhibitor of Oncogenic, Angiogenic, and Stromal Kinases, in Patients with Advanced Solid Tumors , 2012, Clinical Cancer Research.
[7] H. Johnsen,et al. [The clinical research unit]. , 2010, Ugeskrift for laeger.